Millennium Management’s PROVECTUS BIOPHARMACEUTICALS, INC. (DE) PVCT Stock Holding History

Millennium Management’s Portfolio PVCT Stock Details PVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-39,760	Closed	-$15K	–	3882
2016 Q1	$15K	Sell	39,760 -135,478	-77%	-$55.8K	﹤0.01%	3197
2015 Q4	$68K	Sell	175,238 -372,835	-68%	-$177K	﹤0.01%	3289
2015 Q3	$315K	Buy	548,073 +48,073	+10%	+$24.6K	﹤0.01%	2893
2015 Q2	$87K	Buy	+500,000	New	+$408K	﹤0.01%	3191

Other funds holding PVCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

HFBOT

Home Federal Bank of Tennessee Knoxville, Tennessee $463M AUM 24.62% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

CCB

Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return

GW & Wade Wellesley, Massachusetts $3.08B AUM 18.99% 1-Year Est. Return

Millennium Management's PVCT Position: Q2 2016 in Review

Millennium Management sold out of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) in Q2 2016, closing a stake of 39,760 shares — an estimated $15K sold.

Millennium Management first reported a position in PVCT in Q2 2015 and held it in 4 quarters. The position peaked at $315K in Q3 2015. 45 funds tracked by Wall St. Rank hold PVCT as of Q2 2016.

Millennium Management reported no remaining PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position as of Q2 2016 after selling out during the quarter.
Millennium Management sold 39,760 PROVECTUS BIOPHARMACEUTICALS, INC. (DE) shares in Q2 2016, an estimated $15K.
Millennium Management first reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in Q2 2015 and held it in 4 quarters.
Millennium Management's PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position peaked at $315K in Q3 2015.
45 funds tracked by Wall St. Rank held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) as of Q2 2016.

Based on Millennium Management's 13F filing for Q2 2016, filed 15 Aug 2016.